deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT01461213

Gene Therapy for Blindness Caused by Choroideremia

An Open Label Dose Escalation Phase 1 Clinical Trial of Retinal Gene Therapy for Choroideraemia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)

Sponsor: Manchester University NHS Foundation Trust

Conditions Choroideremia
Interventions rAAV2.REP1
Updated 7 times since 2017 Last updated: Nov 16, 2017 Started: Oct 31, 2011 Primary completion: Oct 31, 2017 Completion: Oct 31, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Choroideremia and is currently completed. Manchester University NHS Foundation Trust leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Dec 2017 · 11 months · monthly snapshotActive Not Recruiting~Dec 2017 – ~Apr 2018 · 4 months · monthly snapshotCompleted~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Apr 2018 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

▶ Show 2 earlier versions

  1. Dec 2017 — Apr 2018 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

  2. Jan 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    First recorded

Oct 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Manchester University NHS Foundation Trust
  • Moorfields Eye Hospital NHS Foundation Trust
  • Oxford University Hospitals NHS Trust
  • University College, London
  • University Hospital Southampton NHS Foundation Trust
  • University of Manchester
  • University of Oxford
  • University of Southampton
Data source: University of Oxford

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations